Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6762936 | 0.91 | SMN1; SMN2 (0.44) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Agmatine SCHEMBL23364182 | 0.91 | PAOX (0.44) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL6761035 | 0.89 | PRMT1 (0.48) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL23796915 | 0.89 | KDM4E (0.50) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3444104 | 0.89 | HDAC6 (0.42) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Tiformin SCHEMBL7440384 | 0.89 | SMN1; SMN2 (0.41) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL7439215 | 0.87 | NPY4R (0.44) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4388552 | 0.85 | KDM4E (0.45) | MEN1KMT2ASMN1; SMN2CYP1A2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL9178312 | 0.84 | HDAC6 (0.51) | MEN1KMT2ASMN1; SMN2CYP1A2ALOX15 | |
| Trifluoroacetic Acid SCHEMBL20542913 | 0.84 | MAOA (0.57) | MEN1KMT2ACA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301429-A1 | COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE | RSEM, LIMITED PARTNERSHIP (CA) | 2024-09-12 | — | — | US | claimed |
| US-20240301429-A1 | COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE | RSEM, LIMITED PARTNERSHIP (CA) | 2024-09-12 | — | — | US | disclosed |
| US-12053442-B2 | Methods and compositions for neuroprotection | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-12031137-B2 | Compositions comprising SASP modulators and senescence attenuators and uses thereof for modulating cellular senescence | RSEM, LIMITED PARTNERSHIP (CA) | 2024-07-09 | — | — | US | disclosed |
| EP-4247405-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | The Feinstein Institutes for Medical Research (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20220290122-A1 | METHODS AND AGENTS FOR MODULATING MITOCHONDRIAL NAD LEVELS | DAVID SABATINI, MD, PHD | 2022-09-15 | — | — | US | disclosed |
| WO-2022108963-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220151958-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220098594-A1 | COMPOSITIONS COMPRISING SASP MODULATORS AND SENESCENCE ATTENUATORS AND USES THEREOF FOR MODULATING CELLULAR SENESCENCE | RSEM, LIMITED PARTNERSHIP (CA) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053442-B2 | Methods and compositions for neuroprotection | FABP7, PYGB, BDNF | MEN1 4568/4885KMT2A 4321/4885SMN1; SMN2 35/4885 |
| US-20220151958-A1 | METHODS AND COMPOSITIONS FOR NEUROPROTECTION | FABP7, PYGB, BDNF | MEN1 4568/4885KMT2A 4321/4885SMN1; SMN2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.